Sugi Predict

Sugi Predict / Compounds / SCHEMBL5333971

SCHEMBL5333971

SCHEMBL5333971

Cc1cc2c(nc(CC3CC3)n2CCOCCNC(=O)NC2CCCCC2)c(N)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ RXFP1 Q9HBX9 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ HTT P42858 1/20 0.36
▸ EPHX2 P34913 2/20 0.36
▸ BRD4 O60885 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ TLR8 Q9NR97 2/20 0.35
▸ TLR7 Q9NYK1 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ EPHX1 P07099 4/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332201 0.92 EPHX1 (0.37) POLBHPGDMEN1KMT2ARXFP1
SCHEMBL5338204 0.90 EPHX1 (0.39) POLBHPGDMEN1KMT2ARXFP1
SCHEMBL5341250 0.89 EPHX2 (0.41) POLBHPGDMEN1KMT2ARXFP1
SCHEMBL5341368 0.88 TLR8 (0.39) BRD4TLR8TLR7
SCHEMBL4794976 0.87 TP53 (0.41) POLBMEN1KMT2AKDM4ETSHR
SCHEMBL4793900 0.85 TLR8 (0.41) MEN1KMT2AHTTTLR8TLR7
SCHEMBL5339657 0.84 EPHX2 (0.39) CCR3EPHX2KDM4ETLR8TLR7
SCHEMBL5341245 0.84 EPHX2 (0.37) POLBHPGDMEN1KMT2ARXFP1
SCHEMBL5870450 0.84 HPGD (0.36) POLBHPGDMEN1KMT2ARXFP1
SCHEMBL5344262 0.83 TLR7 (0.36) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 — — US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 — — US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 — — US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 — — US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 — — US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 CCR3 64/4885POLB 3686/4885HPGD 624/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP CCR3 47/4885POLB 3743/4885HPGD 326/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 CCR3 64/4885POLB 3686/4885HPGD 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.